EFEMP2 and endometrial cancer: In our study, we initially detected that low expression of fibulin-4 was associated with poor clinical pathological characteristics of endometrial cancer, and fibulin-4 could inhibit endometrial cancer cell proliferation, invasion and metastasis by preventing EMT via the Wnt/β-catenin pathway.